Loading stock data…
Bausch Health Companies Inc (BHC)
$4.85+0.09 (+1.89%)
Market ClosedLast close Jun 29
Bausch Health Companies Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bausch Health Companies Inc. in the Healthcare sector is trading at $4.85 with a market capitalization of $1.9B. Wall Street consensus targets $7.40 (5 analysts), implying a +52.6% move over the next 12 months. The stock is currently near its 52-week low of $4.57, remaining 19.7% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +52.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.52B↓ | $2.80B↑ | $2.68B↑ | $2.53B↑ | $2.26B |
| Gross Profit | $1.79B↓ | $2.00B↑ | $1.93B↑ | $1.77B↑ | $1.56B |
| Operating Income | $521.00M↓ | $829.00M↑ | $636.00M↑ | $457.00M↑ | $292.00M |
| Net Income | -$1.42B↓ | -$112.00M↓ | $179.00M↑ | $148.00M↑ | -$58.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
58.67%
Volume
Today's trading volume
4.19M
Recent News
Health Care Roundup: Market Talk
Find insight on Apotex Health, GSK’s $10.6 billion acquisition of Nuvalent and more in the latest Market Talks covering Health Care.
Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Bausch Health Companies Was Crawling Higher This Week
Investors liked what they saw with the company's opening 2026 earnings report.
TSX up 455 Points at Midday With Healthcare, Materials, The Best Performers
The Toronto Stock Exchange is up 455 points at midday, partially recouping some of the 630 points lo
BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength
Bausch Health posts mixed Q1: EPS misses, but revenues beat estimates on strong Salix and Solta growth. Pipeline progress and the raised 2026 view add momentum.